NASDAQ · ZURA
Zura Bio Limited
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
Loading market information…
NASDAQ · PYXS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pyxis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pyxis Oncology, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pyxis Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 18, 2025 | -$0.58-75.76% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.35-9.37% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $8.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$11.15-$0.40 (-3.46%)
Enanta Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.99% below the high.
$4.02+$0.03 (+0.75%)
Immuneering Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.59% below the high.
$0.47-$0.00 (-0.06%)
Humacyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.36% below the high.
$2.09-$0.04 (-1.88%)
Foghorn Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.54% below the high.
$1.76-$0.08 (-4.35%)
Voyager Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.88% below the high.
$0.40-$0.01 (-1.34%)
Tenaya Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.46% below the high.
